Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative Colitis
Status:
Completed
Trial end date:
2018-08-21
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of vedolizumab subcutaneous (vedolizumab
SC) maintenance treatment on clinical remission at Week 52 in participants with moderately to
severely active ulcerative colitis (UC) who achieved clinical response following
administration of vedolizumab intravenous (vedolizumab IV) induction therapy.